“U.S. Navy and Solazyme to develop algae-derived advanced biofuel - News-Medical.Net” plus 4 more |
- U.S. Navy and Solazyme to develop algae-derived advanced biofuel - News-Medical.Net
- Study Reveals New Role of Vitamin C in Skin Protection - PhysOrg
- Constellation Pharmaceuticals Appoints Renowned Cancer Biologist ... - Phramalive.com
- AHS, AJH welcomes new teachers - Ada Evening News
- Wray Herbert - Newsweek
| U.S. Navy and Solazyme to develop algae-derived advanced biofuel - News-Medical.Net Posted: 09 Sep 2009 03:19 AM PDT Solazyme, Inc., the renewable oil production company and leader in algal synthetic biology, has been selected by the U.S. Department of Defense (DoD) to research, develop, and demonstrate commercial scale production of algae-derived advanced biofuel that meets the United States Navy's rigorous specifications for military tactical platforms. Solazyme will utilize its innovative large-scale algal oil production process to provide renewable F-76 Naval Distillate fuel for testing and fuel certification to demonstrate it meets all military specifications and functional requirements. The contract will further advance research and development on large scale advanced biofuel production from algae. It includes both R&D and fuel delivery components and calls for delivery of over 20,000 gallons of Soladiesel®F-76 Renewable Naval Distillate fuel to the Navy for compatibility testing over the next year. F-76 Naval Distillate is similar to diesel fuel and is the primary shipboard fuel used by the Navy. "The fuels made with our algal technology reduce greenhouse gas emissions by over 85% versus standard petroleum based fuels," said Jonathan Wolfson, Solazyme's CEO. "We are honored to be working with the U.S. Navy to develop one of the world's newest and cleanest fuels." "The Navy, the Defense Energy Support Center, the Defense Logistics Agency and the entire Department of Defense, have taken a true leadership position in moving forward to utilize clean and renewable oil production technology to address both the national energy security needs of our country and the environmental challenges facing our planet," Wolfson added. Solazyme's technology will help the DoD reduce its carbon footprint, combat global climate change and lead in the development of clean and renewable energy sources. Reducing our dependence on foreign oil is a national security imperative, and Solazyme's technology focuses on producing an abundant, domestic and renewable source for oil and fuels. Solazyme has already produced Soladiesel®F-76 that has been delivered to the Department of Defense for initial testing and has met the Navy's F-76 specification. This program will lead to the eventual certification of Soladiesel®F-76 Naval distillate for commercial sale to the U.S. Military. | |
| Study Reveals New Role of Vitamin C in Skin Protection - PhysOrg Posted: 09 Sep 2009 07:51 AM PDT Study Reveals New Role of Vitamin C in Skin ProtectionSeptember 9th, 2009(PhysOrg.com) -- Scientists have uncovered a new role played by Vitamin C in protecting the skin. Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration. The work, by Tiago Duarte, Marcus S. Cooke and G. Don Jones, found that a form of Vitamin C helped to promote wound healing and also helped protect the DNA damage of skin cells. Their findings have been published in the journal Free Radical Biology and Medicine. This report is the latest in a long line of publications from these researchers, at the University of Leicester, concerning vitamin C. Previously, the group has published evidence that DNA repair is upregulated in people consuming vitamin C supplements. The researchers have now provided some mechanistic evidence for this, in cell culture, using techniques such as Affymetrix microarray, for looking at gene expression, and the Comet assay to study DNA damage and repair. Tiago Duarte, formerly of the University of Leicester, and now at the Institute for Molecular and Cellular Biology in Portugal, said: The exposure to solar ultraviolet radiation increases in summer, often resulting in a higher incidence of skin lesions. Ultraviolet radiation is also a genotoxic agent responsible for skin cancer, through the formation of free radicals and DNA damage. Our study analysed the effect of sustained exposure to a vitamin C derivative, ascorbic acid 2-phosphate (AA2P), in human dermal fibroblasts. We investigated which genes are activated by vitamin C in these cells, which are responsible for skin regeneration. The results demonstrated that vitamin C may improve wound healing by stimulating quiescent fibroblasts to divide and by promoting their migration into the wounded area. Vitamin C could also protect the skin by increasing the capacity of fibroblasts to repair potentially mutagenic DNA lesions. Even though vitamin C was discovered over 70 years ago as the agent that prevents scurvy, its properties are still under much debate in the scientific community. In fact, the annual meeting of the International Society for Free Radical Biology and Medicine, which will be held this year in San Francisco (USA), will feature a session dedicated to vitamin C, entitled New discoveries for an old vitamin". Dr Marcus S. Cooke from the Department of Cancer Studies and Molecular Medicine and Department of Genetics, at the University of Leicester, added: The study indicates a mechanism by which vitamin C could contribute to the maintenance of a healthy skin by promoting wound healing and by protecting cellular DNA against damage caused by oxidation. These findings are particular importance to our photobiology interests, and we will certainly be looking into this further. These results will be of great relevance to the cosmetics industry. Free radicals are associated with premature skin aging, and antioxidants, such as vitamin C, are known to counter these highly damaging compounds. This new evidence suggest that, in addition to mopping up free radicals, vitamin C can help remove the DNA damage they form, if they get past the cells defences. The study has the potential to lead to advances in the prevention and treatment of skin lesions specifically, as well as contributing to the fight against cancer.
Provided by University of Leicester (news : web) | |
| Constellation Pharmaceuticals Appoints Renowned Cancer Biologist ... - Phramalive.com Posted: 09 Sep 2009 09:17 AM PDT -Company Leading Emerging Field of Epigenetics- Dr. Harlow, a distinguished molecular biologist, is an internationally recognized leader in cancer biology who is best known for his discoveries regarding the control of cell division and critical changes that allow cancer to develop. He most recently served as Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Associate Director of the Dana-Farber/Harvard Cancer Center. Previously he served as Scientific Director for the Massachusetts General Hospital Cancer Center and was Associate Director for Science Policy at the National Cancer Institute, where he helped direct U.S. cancer research planning. Dr. Harlow has received numerous scientific honors, including election to the National Academy of Sciences and the Institute of Medicine, appointment as Fellow of the American Academy of Arts and Sciences, and receipt of the American Cancer Society's highest award, the Medal of Honor. "We are delighted and proud that Ed is joining the leadership of Constellation at this pivotal point as we grow our team and make important progress with our R&D programs," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer of Constellation Pharmaceuticals. "He has an outstanding record of achievement in science and he has collaborated with and advised both young and established pharmaceutical companies. Our company is built on a tradition of rigorous science, and Ed's proven ability to lead breakthrough research coupled with his deep relationships across academia and industry will help us to achieve high impact on behalf of patients." "I am excited to join this impressive organization and believe the depth and quality of Constellation's scientists and drug discovery platform position it to continue leading the field," said Dr. Harlow. "Epigenetics is an intriguing window into the complex biology of multiple diseases, and Constellation offers a compelling opportunity to leverage my experience in order to create innovative medicines." Dr. Harlow has served on a number of influential advisory groups, including the Board of Life Sciences for the National Research Council, External Advisory Boards for UCSF, Stanford, UCLA, and NYU Cancer Center, and Scientific Advisory Boards for the Foundation for Advanced Cancer Studies and numerous biotechnology and pharmaceutical companies, including Onyx, Alnylam, 3V Biosciences, and Pfizer Pharmaceuticals. He received his B.S. and M.S. from the University of Oklahoma and his Ph.D. at the Imperial Cancer Research Fund in London. About Constellation Pharmaceuticals Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science that focuses on selective regulators of gene function and expression. Constellation's initial focus is in oncology, and the Company's platform will also be applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases. The Company's academic founders represent the core thought leaders in epigenetics responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.constellationpharma.com. Constellation Pharmaceuticals was founded by three of the foremost authorities and leaders within the field of Epigenetics: Danny Reinberg, Ph.D, Professor of Biochemistry at the New York University School of Medicine and an Investigator of the Howard Hughes Institute; Yang Shi, Ph.D., Professor of Pathology at the Harvard Medical School and David Allis, Ph.D., Professor and Head of the Laboratory of Chromatin Biology at The Rockefeller University. Constellation's Board of Directors include: Anthony Evnin, Partner, Venrock; David Goeddel, Ph.D., Partner, The Column Group; Mark Levin, Partner, Third Rock Ventures; Tom Maniatis, Ph.D., Professor, Harvard University; Robert Tepper, M.D., Partner, Third Rock Ventures; and Mark A. Goldsmith, M.D., Ph.D., CEO, Constellation Pharmaceuticals. Also supporting the Company's efforts is a Scientific Advisory Board featuring some of the most renowned scientific experts within the field of Epigenetics and oncology, including; Richard Klausner, M.D., Managing Partner, The Column Group and former Director of the National Cancer Institute; Arnold Levine, Ph.D., Professor, Institute of Advanced Study; David Livingston, M.D., Deputy Director, Dana Farber/Harvard Cancer Institute; Julian Adams, Ph.D., Chief Scientific Officer, Infinity Pharmaceuticals; Xiaodong Cheng, Ph.D., Professor, Emory University; Thomas Jenuwein, Ph.D., Director, Max Planck Institute; and Scott Lowe, Ph.D., Professor, Cold Spring Harbor Laboratory. About Epigenetics Epigenetics is an exciting new field of biology that involves chemical modifications of both DNA and of its packaging proteins ("chromatin"), which are collectively called the ˜epigenome.' The genome, or DNA, is the "blueprint" for the human body, consisting of thousands of genes, which are the fundamental units of information necessary for normal cell growth and development. In contrast, the epigenome plays a critical role in regulating the expression of genes, that is, switching genes on or off – or in the case of disease, for switching genes on or off incorrectly. This new field of Epigenetic science provides the opportunity to create a broad new class of human therapeutics targeting selective regulators of epigenetic function.
Contact: Yates Public Relations Kathryn Morris, 845-635-9828 ***
| |
| AHS, AJH welcomes new teachers - Ada Evening News Posted: 09 Sep 2009 09:24 AM PDT | Published: September 09, 2009 11:21 am AHS, AJH welcomes new teachers Joe Claxton ACS Publications DirectorAda — A total of 21 new teachers will greet the students returning to Ada City Schools on Aug. 17. Seven will be at Ada High, Ada Junior High or the Alternative Academy. Natalie Hughes will join Dustin Ford as the new teachers at AJH. Hughes will be the new Family and Consumer Sciences teacher and Ford will be the In School Restriction teacher. Hughes, a 1996 graduate of Lexington, taught at that school in the 2002-03 school year. She has a BS from ECU in 2001. Hughes is married to Brian Hughes, a 1996 AHS grad, and they have two children, Indy Gwin Hughes, 5, kindergarten, and Andrew Douglas Hughes, 4, pre-k. Ford is a 2003 grad of Okemah and earned his bachelors from ECU in the spring. He is a first-year teacher and was a grad assistant with the AHS baseball team last season. Ford joins two other bachelors in the AJH-AHS-Alternative Academy ranks. Elliott Alberson is at the Alternative Academy on the AHS campus. A 2001 AHS grad, Alberson has one year of experience at Dibble. He is a 2007 ECU grad and is working on his masters and will also coach baseball. Darin Kapella, the newest member of the AHS football staff, will teach Algebra I and II at AHS. A 1996 Davis graduate, he received his bachelors in Math Ed from Arkansas Tech University in 2001. He has taught and coached since 2001-02 at five schools in Texas and Arkansas. His last stop was McKinney (TX) High School, where he taught geometry 2007-09. Three more teachers bolster the high school staff. Jayna Moore is the new marketing instructor and will handle CNN, the school's in-house television network that is also shown on CableOne Channel 19. She taught at the Pontotoc Tech Center and Murray State 2004-09 as tech prep coordinator and alliance coordinator. Moore and husband Ty have two children, Kane, 12, 6th grade; and Trel, 9, 4th. She is a 1990 Hulbert grad with a BS in business administration/marketing from ECU; and a teaching certificate in business education and career tech education in 2004. Shawn Freeman, a 1987 McLish grad, joins the AHS science department, teaching biology and earth science. Freeman and husband Bobby have three children; T.J., 14, 9th; Morganne, 10, 5th; and Makayla, 7, 2nd. Her experience includes three years at Springtown, TX, 1995-98, teaching chemistry; and two at Roff, 1992-94, teaching biology, chemistry and general science. Freeman graduated from Cameron in 1992 and received a teaching certificate the following year. She earned her masters from ECU in 1995. Ali Lawson will take over the leadership classes. A 2004 AHS grad, she received her BS in business administration in 2008 from ECU, and also served as recruiter at that school last year. She is married to another AHS grad, Blake Lawson. 
|
| Posted: 09 Sep 2009 09:45 AM PDT Sucking Up Has Its LimitsRemember the apple polisher? In my school days, apple polishers were kids who kissed up to the teacher. They would tell their biology teacher, I've wanted to be a biologist since I was 3; or say to the English instructor, I'm reading Faulkner's novels on my own time, just for fun. They'd ask for permission to work ahead. |
| You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
0 comments:
Post a Comment